arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Gossamer Bio, Inc.

GOSS
$10.94 ▼ -0.78 (-6.66%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
46
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Gossamer Bio, Inc. faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $3.5B
Dividend Yield
Revenue Growth -19.6%
Op. Margin -282.2%
ROIC 21.9%
FCF / Share $-0.12
Trailing P/E 218.8x
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.24M
↓ -19.6%
Net Income Profit after all expenses
$-46.66M
↓ -27.4%
Operating Margin Operating profit as % of sales
-282.2%
↓ -6.7% 0th
FCF / Share Free cash flow per share
$-0.12
↑ +25.5%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
100
Financial Health
26
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 36 quarters